Saturday 17 October 2026
Export ABVX’s income statement to Excel — free account
Abivax SA Sponsored ADR
ABVX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 98.8%, free cash flow fell 48.3% and total debt fell 98.5%, each against the same quarter a year earlier.
87.78
4.60
−4.98%
Follow ABVX
Abivax SA Sponsored ADR (ABVX) P/E ratio
Abivax SA Sponsored ADR has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SYRE Spyre Therapeutics, Inc. compare | n/m |
| ABVX Abivax SA Sponsored ADR | n/m |
| CYTK Cytokinetics, Incorporated compare | n/m |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | n/m |
| AXSM Axsome Therapeutics, Inc. compare | n/m |
| IONS Ionis Pharmaceuticals, Inc. compare | n/m |
| TGTX TG Therapeutics, Inc. compare | 17.8× |
| CAI Caris Life Sciences,�Inc. compare | 81.3× |
| PTGX Protagonist Therapeutics, Inc. compare | 106× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)